Cognition Therapeutics (CGTX) said Wednesday that a phase 2 study of CT1812 to treat patients with Lewy body dementia met its primary endpoint of safety and tolerability.
The drug produced "strong therapeutic responses across behavioral, functional, cognitive and movement measures" in patients who received the treatment for six months, compared to placebo.
The results showed a 82% slowing in neuropsychiatric inventory decline and a 91% reduction in attention fluctuations, while reducing anxiety, hallucinations and delusions, Cognition said.
The company said it expects to review the results with the Food and Drug Administration in an end-of-phase 2 meeting and to advance CT1812 into late-stage trials.
Cognition Therapeutics shares were 135% higher in recent premarket trading.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。